TomographyXtra LasikNCT06857032
Long-term Safety and Effectiveness of LASIK-Xtra Compared to Conventional LASIK
An observational study of Tomography and Corneal Biomechanics, run by University Clinic Frankfurt at 1 site in Germany.
Trial summary
Laser in situ keratomileusis (LASIK) is a widely used procedure for the correction of myopia and myopic astigmatism. Despite its high effectiveness and the general safety of the procedure, long-term safety and effectiveness remain a key concern in ophthalmology. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tomography, Corneal Biomechanics, Manifest Ref
- How many people
- 12 participants
- Where
- 1 siteGermany
- Study dates
- 1 Aug 2024to Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated with Xtralasik and participated in the first XtraLasik study
Who may be able to join
- For both the retrospective and prospective part of the study:
- only patients who have successfully participated in the study with the clinicaltrials.gov registration number NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt will be included for the study to assess long-term outcomes and safety.
- adult men or women over the age of 18.
- subjects must be able to understand the requirements of the study and provide written informed consent.
Who cannot join
- Applies only to patients participating in the prospective part of the study:
- 1. employees, relatives or friends of employees of an ophthalmological company or investigational clinic (e.g. investigator, coordinator, technician)
Trial locations and contacts
1 site in 1 country.
Germany1 site
University Clinic Frankfurt, Goethe University
Frankfurt am Main, Hesse, 60590
About this study
Official title: Evaluation of the Long-term Safety and Effectiveness of Laser in Situ Keratomileusis (LASIK) in Combination With Corneal UV-riboflavin Crosslinking in Comparison With Classic LASIK for the Correction of Myopia and Myopic Astigmatism
Laser in situ keratomileusis (LASIK) is a widely used procedure for the correction of myopia and myopic astigmatism. Despite its high effectiveness and the general safety of the procedure, long-term safety and effectiveness remain a key concern in ophthalmology. A promising further development is the combination of LASIK with corneal UV-riboflavin crosslinking, which promises additional stability of the cornea.1 This study aims to evaluate the long-term safety and effectiveness of this combined method in comparison to classic LASIK. By analysing long-term results, the aim is to gain well-founded insights that will help to optimise the decision on the most suitable procedure for correcting myopia and myopic astigmatism and to ensure the best possible clinical results for patients.
Read the detailed description
The null hypothesis is that combined laser in situ keratomileusis (LASIK) with corneal UV-riboflavin crosslinking (LASIK-Xtra) has the same long-term safety and effectiveness as classic LASIK for the correction of myopia and myopic astigmatism.
Aim of the study The main objective of this study is to determine whether LASIK-Xtra compared to classic femto-LASIK
- leads to the same long-term results in terms of postoperative visual acuity,
- the postoperative spectacle values of both eyes are at least equally stable over several years after the study and
- the corneal shape and stiffness values do not differ between the procedures after several years.
In addition, possible long-term side effects of the procedures are documented.
The new ophthalmological examination is intended to show that the combination of LASIK-Xtra is at least equally safe and effective compared to the standard variant of Femto-LASIK even after several years.
Safety endpoints:
For the entire study:
- difference between preoperative and postoperative best corrected visual acuity (BCDVA)
- occurrence of keratoectatic changes
- incidence of adverse events study design
- The retrospective-prospective study includes:
- a retrospective collection of examination and surgical results of patients who successfully participated in the study with the clinicaltrials.gov registration number: NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt
- a prospective follow-up examination in accordance with the standard in ophthalmology to record the visual acuity and eye examination data of patients who were treated between 2014 and 2018 at the Department of Ophthalmology at Goethe University Frankfurt for the correction of myopia and myopic astigmatism in one eye using LASIK-Xtra and in the partner eye using classic femto-LASIK as part of the above-mentioned study
- Performance of non-invasive examinations to assess long-term safety and effectiveness
- De-personalised data collection via MS Excel for Mac (Version 16.53, Microsoft, USA)
- Statistical analysis using SPSS Statistic 29 software (IBM, USA)
- Data security: Data storage is pseudonymised and password-protected material \& methods
Retrospective part:
As part of the study, available visual acuity, results of surgery and examination results already available in the study files of patients who have undergone surgery as part of the NCT 03913338 study will be collected.
No measures will be collected other than those already available in the patient file at the study centre.
Prospective part:
Patients who fulfil the eligibility criteria and agree to participate in the prospective study will be asked to come to the clinic for a single study visit to perform a standard ophthalmological examination in ophthalmology. These include:
Slit lamp examination:
During the study visit, a slit lamp examination will be performed. Particular attention is paid to the cornea. The clarity and quality of the epithelium and stroma will be assessed. All results, including any changes, must be recorded in the patient file and CRF. Photographic documentation is taken.
Subjective refraction:
Basically, subjective refraction is based on the patient\'s response to changes in lens power and their orientation in relation to the legibility of certain vision charts. This method requires the patient\'s concentration and co-operation and must be performed by either an optician or ophthalmologist.
Pentacam® AXL Wave (Oculus, Wetzlar, Germany):
This tool is one of the latest ophthalmological measurement devices. The measuring principle is based on a combination of slit illumination and Scheimpflug camera. During data acquisition, the sensors rotate around the eye. It combines the following functions: Scheimpflug tomography, wavefront measurement of the entire eye, objective refraction, axial globe length measurement and retroillumination. All data is collected in one scan within the same measurement axis.
iTrace (Tracey Technologies, Texas, USA): This ray tracing based diagnostic tool offer two different functions: Wavefront measurement and corneal topography. The built-in processor unit allows iTrace (Tracey Technologies, Texas, USA) to calculate additional data (e.g. differentiation between internal optics and total aberration).
Corvis ST® (Oculus, Wetzlar, Germany):
This instrument is a non-contact tonometer that analyses the cornea\'s response to an air pressure pulse using an ultra-high-speed Scheimpflug camera. The recorded image sequences are used to estimate the intraocular pressure and deformation parameters. All measurements with the Corvis ST are performed in a seated position with the pupil undilated.
Nidek CEM-530 (Nidek Co, Gamagori, Japan):
This is a non-contact spectral microscope for measuring the number and evaluating the shape of the corneal endothelium. Due to the non-contact measurement, there is no risk of corneal infection and no anaesthesia is required.
The measurements are performed by trained and certified staff of the study centre of the Department of Ophthalmology of the Goethe University Hospital.
Patient recruitment:
The patients who successfully participated in the study entitled 'Controlled evaluation of the safety and effectiveness of laser in situ keratomileusis (LASIK) for the correction of myopia and myopic astigmatism in combination with corneal UV riboflavin crosslinking with the KXL system and VibeX Xtra riboflavin eye drops compared to classic LASIK. ' successfully participated in the study period from 2014 to 2018 at the Department of Ophthalmology at Goethe University Frankfurt (clinicaltrials.gov, registration number: NCT 03913338) will be informed about the current study by telephone or electronically via e-mail by employees of the study centre. This involves 19 patients. After giving their consent, they will be invited to the Department of Ophthalmology on an agreed date. This is based on the contact details stored in the study files.
All individuals will be appropriately informed and explicitly informed about the voluntary nature of their participation. Further information can be found in the document 'Patient information and consent form'.
The parameters of the measurements taken during the initial study will be collected from the study file.
6 Data collection The collection of personal patient data is carried out in compliance with the Data Protection Act. The data subject is recorded exclusively via a numerical ID.
statistics The analysis is carried out with SPSS Statistic 29 (IBM, USA). The Shapiro-Wilk test is used to test the normal distribution. The Wilcoxon rank sum test (non-parametric) and the paired t-test (parametric data) are used to determine differences between the different time points. A descriptive data analysis is also carried out.
Case number calculation:
Since the study results are purely descriptive in nature, the sample size is based on the total number of subjects who successfully participated in the study. We expect to collect data from a total of 19 patients (38 eyes) from previous surgeries with LASIK Xtra on one eye and conventional Femto-LASIK on the fellow eye.
Inclusion and exclusion criteria:
Inclusion criteria
For both the retrospective and prospective part of the study:
- only patients who have successfully participated in the study with the clinicaltrials.gov registration number NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt will be included for the study to assess long-term outcomes and safety.
- adult men or women over the age of 18.
- subjects must be able to understand the requirements of the study and provide written informed consent.
Exclusion criteria
Applies only to patients participating in the prospective part of the study:
- employees, relatives or friends of employees of an ophthalmological company or investigational clinic (e.g. investigator, coordinator, technician)
- Conditions
- Tomography, Corneal Biomechanics, Manifest Ref, Endothelial Cells, IOP, Optical Coherence Tomography
- Keywords
- Lasik, Lasik Xtra, Keratectasia, Corneal biomechanics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Patients treated with Xtralasik |
What is being measured
The primary outcome is the main question the study is designed to answer.
Manifest refraction
Manifest refraction with trial frame
Measured: single time point with one and only visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2025
- Study start1 Aug 2024
- Primary completion31 Dec 2024
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for TomographyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Clinic Frankfurt
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Professor Dr. med. Thomas Kohnen, University Clinic Frankfurt
- Investigators
- Thomas Kohnen, Professor and Doctor, Principal investigator, University Hospital Frankfurt am Main - Eye clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06857032
- Sponsor's protocol ID
- 0219-2024
- Acronym
- Xtra Lasik
- Status last verified
- Sep 2024
- First submitted
- 26 Feb 2025
- Last updated
- 4 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kohnen T, Lwowski C, Hemkeppler E, de'Lorenzo N, Petermann K, Forster R, Herzog M, Bohm M. Comparison of Femto-LASIK With Combined Accelerated Cross-linking to Femto-LASIK in High Myopic Eyes: A Prospective Randomized Trial. Am J Ophthalmol. 2020 Mar;211:42-55. doi: 10.1016/j.ajo.2019.10.024. Epub 2019 Nov 1.
PubMed 31678559
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Long-term Safety and Effectiveness of Laser in Situ Keratomileusis (LASIK) in Combination With Corneal UV-riboflavin Crosslinking in Comparison With Classic LASIK for the Correction of Myopia and Myopic Astigmatism
- ClinicalTrials.gov ID
- NCT06857032
- Acronym / sponsor ID
- Xtra Lasik / 0219-2024
- Conditions
- Tomography, Corneal Biomechanics, Manifest Ref, Endothelial Cells, IOP, Optical Coherence Tomography
- Keywords
- Lasik, Lasik Xtra, Keratectasia, Corneal biomechanics
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- University Clinic FrankfurtUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- Dec 2025 (estimated)
- First posted
- 4 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Laser in situ keratomileusis (LASIK) is a widely used procedure for the correction of myopia and myopic astigmatism. Despite its high effectiveness and the general safety of the procedure, long-term safety and effectiveness remain a key concern in ophthalmology. A promising further development is the combination of LASIK with corneal UV-riboflavin crosslinking, which promises additional stability of the cornea.1 This study aims to evaluate the long-term safety and effectiveness of this combined method in comparison to classic LASIK. By analysing long-term results, the aim is to gain well-founded insights that will help to optimise the decision on the most suitable procedure for correcting myopia and myopic astigmatism and to ensure the best possible clinical results for patients.
Detailed description
The null hypothesis is that combined laser in situ keratomileusis (LASIK) with corneal UV-riboflavin crosslinking (LASIK-Xtra) has the same long-term safety and effectiveness as classic LASIK for the correction of myopia and myopic astigmatism.
Aim of the study The main objective of this study is to determine whether LASIK-Xtra compared to classic femto-LASIK
- leads to the same long-term results in terms of postoperative visual acuity,
- the postoperative spectacle values of both eyes are at least equally stable over several years after the study and
- the corneal shape and stiffness values do not differ between the procedures after several years.
In addition, possible long-term side effects of the procedures are documented.
The new ophthalmological examination is intended to show that the combination of LASIK-Xtra is at least equally safe and effective compared to the standard variant of Femto-LASIK even after several years.
Safety endpoints:
For the entire study:
- difference between preoperative and postoperative best corrected visual acuity (BCDVA)
- occurrence of keratoectatic changes
- incidence of adverse events study design
- The retrospective-prospective study includes:
- a retrospective collection of examination and surgical results of patients who successfully participated in the study with the clinicaltrials.gov registration number: NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt
- a prospective follow-up examination in accordance with the standard in ophthalmology to record the visual acuity and eye examination data of patients who were treated between 2014 and 2018 at the Department of Ophthalmology at Goethe University Frankfurt for the correction of myopia and myopic astigmatism in one eye using LASIK-Xtra and in the partner eye using classic femto-LASIK as part of the above-mentioned study
- Performance of non-invasive examinations to assess long-term safety and effectiveness
- De-personalised data collection via MS Excel for Mac (Version 16.53, Microsoft, USA)
- Statistical analysis using SPSS Statistic 29 software (IBM, USA)
- Data security: Data storage is pseudonymised and password-protected material \& methods
Retrospective part:
As part of the study, available visual acuity, results of surgery and examination results already available in the study files of patients who have undergone surgery as part of the NCT 03913338 study will be collected.
No measures will be collected other than those already available in the patient file at the study centre.
Prospective part:
Patients who fulfil the eligibility criteria and agree to participate in the prospective study will be asked to come to the clinic for a single study visit to perform a standard ophthalmological examination in ophthalmology. These include:
Slit lamp examination:
During the study visit, a slit lamp examination will be performed. Particular attention is paid to the cornea. The clarity and quality of the epithelium and stroma will be assessed. All results, including any changes, must be recorded in the patient file and CRF. Photographic documentation is taken.
Subjective refraction:
Basically, subjective refraction is based on the patient\'s response to changes in lens power and their orientation in relation to the legibility of certain vision charts. This method requires the patient\'s concentration and co-operation and must be performed by either an optician or ophthalmologist.
Pentacam® AXL Wave (Oculus, Wetzlar, Germany):
This tool is one of the latest ophthalmological measurement devices. The measuring principle is based on a combination of slit illumination and Scheimpflug camera. During data acquisition, the sensors rotate around the eye. It combines the following functions: Scheimpflug tomography, wavefront measurement of the entire eye, objective refraction, axial globe length measurement and retroillumination. All data is collected in one scan within the same measurement axis.
iTrace (Tracey Technologies, Texas, USA): This ray tracing based diagnostic tool offer two different functions: Wavefront measurement and corneal topography. The built-in processor unit allows iTrace (Tracey Technologies, Texas, USA) to calculate additional data (e.g. differentiation between internal optics and total aberration).
Corvis ST® (Oculus, Wetzlar, Germany):
This instrument is a non-contact tonometer that analyses the cornea\'s response to an air pressure pulse using an ultra-high-speed Scheimpflug camera. The recorded image sequences are used to estimate the intraocular pressure and deformation parameters. All measurements with the Corvis ST are performed in a seated position with the pupil undilated.
Nidek CEM-530 (Nidek Co, Gamagori, Japan):
This is a non-contact spectral microscope for measuring the number and evaluating the shape of the corneal endothelium. Due to the non-contact measurement, there is no risk of corneal infection and no anaesthesia is required.
The measurements are performed by trained and certified staff of the study centre of the Department of Ophthalmology of the Goethe University Hospital.
Patient recruitment:
The patients who successfully participated in the study entitled 'Controlled evaluation of the safety and effectiveness of laser in situ keratomileusis (LASIK) for the correction of myopia and myopic astigmatism in combination with corneal UV riboflavin crosslinking with the KXL system and VibeX Xtra riboflavin eye drops compared to classic LASIK. ' successfully participated in the study period from 2014 to 2018 at the Department of Ophthalmology at Goethe University Frankfurt (clinicaltrials.gov, registration number: NCT 03913338) will be informed about the current study by telephone or electronically via e-mail by employees of the study centre. This involves 19 patients. After giving their consent, they will be invited to the Department of Ophthalmology on an agreed date. This is based on the contact details stored in the study files.
All individuals will be appropriately informed and explicitly informed about the voluntary nature of their participation. Further information can be found in the document 'Patient information and consent form'.
The parameters of the measurements taken during the initial study will be collected from the study file.
6 Data collection The collection of personal patient data is carried out in compliance with the Data Protection Act. The data subject is recorded exclusively via a numerical ID.
statistics The analysis is carried out with SPSS Statistic 29 (IBM, USA). The Shapiro-Wilk test is used to test the normal distribution. The Wilcoxon rank sum test (non-parametric) and the paired t-test (parametric data) are used to determine differences between the different time points. A descriptive data analysis is also carried out.
Case number calculation:
Since the study results are purely descriptive in nature, the sample size is based on the total number of subjects who successfully participated in the study. We expect to collect data from a total of 19 patients (38 eyes) from previous surgeries with LASIK Xtra on one eye and conventional Femto-LASIK on the fellow eye.
Inclusion and exclusion criteria:
Inclusion criteria
For both the retrospective and prospective part of the study:
- only patients who have successfully participated in the study with the clinicaltrials.gov registration number NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt will be included for the study to assess long-term outcomes and safety.
- adult men or women over the age of 18.
- subjects must be able to understand the requirements of the study and provide written informed consent.
Exclusion criteria
Applies only to patients participating in the prospective part of the study:
- employees, relatives or friends of employees of an ophthalmological company or investigational clinic (e.g. investigator, coordinator, technician)
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | –Patients treated with Xtralasik |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated with Xtralasik and participated in the first XtraLasik study
Key inclusion criteria (4 listed)
- only patients who have successfully participated in the study with the clinicaltrials.gov registration number NCT 03913338 during the study period from 2014 to 2018 at the Department of Ophthalmology of the Goethe University Frankfurt will be included for the study to assess long-term outcomes and safety.
- adult men or women over the age of 18.
- subjects must be able to understand the requirements of the study and provide written informed consent.
Key exclusion criteria (2 listed)
- 1. employees, relatives or friends of employees of an ophthalmological company or investigational clinic (e.g. investigator, coordinator, technician)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Manifest refraction
Time frame: single time point with one and only visit
Manifest refraction with trial frame
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2025.
- Results publication: PubMed 31678559Kohnen T, Lwowski C, Hemkeppler E, de'Lorenzo N, Petermann K, Forster R, Herzog M, Bohm M. Comparison of Femto-LASIK With Combined Accelerated Cross-linking to Femto-LASIK in High Myopic Eyes: A Prospective Randomized Trial. Am J Ophthalmol. 2020 Mar;211:42-55. doi: 10.1016/j.ajo.2019.10.024. Epub 2019 Nov 1.
- Individual participant dataSharing planned: No
Related trials for Tomography
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Not yet recruiting
Regional Lung Ventilation During Prone Position in in Intubated Children
Pediatric Acute Respiratory Failure
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingPhase 1
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Kohnen, Professor and Doctor principal investigator
University Hospital Frankfurt am Main - Eye clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tomography and Corneal Biomechanics, run by University Clinic Frankfurt at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Manifest refraction (time frame: single time point with one and only visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06857032, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2025.